Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Flexible ureteroscopy for renal stones comparing non suction conventional UAS vs flexible and navigable suction ureteral access sheaths in a multicenter real-world experience. Is it finally time to bury the no suction ureteral access sheath? An EAU endourology analysis.

World journal of urology·2025

Same author

Exploring the Link Between Obligate Anaerobe-Related Dysbiosis and Prostate Cancer Development: A Pilot Study.

Cancers·2025

Same author

Diagnosing prostate cancer at a curable stage means providing PSA tests to asymptomatic patients.

BMJ (Clinical research ed.)·2022

Same author

Assessing Ethnic Inequalities in Diagnostic Interval of Common Cancers: A Population-Based UK Cohort Study.

Cancers·2022

Same author

Ethnic inequalities in routes to diagnosis of cancer: a population-based UK cohort study.

British journal of cancer·2022

Same author

Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study.

The Lancet. Oncology·2022

Same journal

Cancer detection in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

BJU international·2026

Same journal

Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC.

BJU international·2026

Same journal

A call for regimen agnostic circulating tumour DNA-guided adjuvant selection in muscle-invasive bladder cancer.

BJU international·2026

Same journal

Ablative radiotherapy in castration-resistant prostate cancer.

BJU international·2026

Same journal

Longitudinal circulating tumour DNA identifies patients at high risk of upstaging and recurrence in non-muscle-invasive bladder cancer.

BJU international·2026

Same journal

Venous thromboembolism after penile cancer surgery: a UK PeCaN study.

BJU international·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 29, 2026

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

Treating stuttering priapism.

Pejman Kheirandish¹, Frank Chinegwundoh, Shailesh Kulkarni

¹Department of Urology, Newham University Hospital, London, UK. k_pejman@hotmail.com

BJU International

|September 15, 2011

Summary

This summary is machine-generated.

Stuttering priapism, a recurrent form of ischemic priapism, involves painful erections that can lead to permanent erectile dysfunction if untreated. More research is needed to establish effective management strategies for this condition.

More Related Videos

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Related Experiment Videos

Last Updated: May 29, 2026

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Urology
Andrology
Sexual Medicine

Background:

Stuttering priapism is an uncommon, recurrent form of ischemic priapism characterized by episodes of painful erections lasting less than 3 hours.
Untreated stuttering priapism can progress to classic ischemic priapism, potentially causing irreversible corporal fibrosis and permanent erectile dysfunction.

Purpose of the Study:

To review the current literature on stuttering priapism.
To highlight the need for further research and standardized treatment protocols.

Main Methods:

A comprehensive literature search was conducted in August 2010 using PubMed, MEDLINE, and general search engines.
Search terms included "stuttering priapism" and "recurrent priapism".

Main Results:

The search identified a significant number of case reports, reviews, anecdotal reports, and small clinical trials.
While understanding of the pathophysiology has improved, evidence from large-scale trials is limited.

Conclusions:

Further multicenter randomized clinical trials are essential to evaluate treatment efficacy for stuttering priapism.
Defining safe and effective management strategies for low-flow recurrent priapism is a critical unmet need.